Studies of AIDS Vaccination Using an Ex Vivo Feline Immunodeficiency Virus Model: Protection Conferred by a Fixed-cell Vaccine Against Cell-free and Cell-associated Challenge Differs in Duration and is Not Easily Boosted

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 1997 Oct 29

PMID 9343192

Citations 14

Authors

D Matteucci

M Pistello

P Mazzetti

S Giannecchini

D Del Mauro

I Lonetti

L Zaccaro

C Pollera

S Specter

M Bendinelli

Affiliations

Soon will be listed here.

Abstract

Cats immunized with cells infected with a primary isolate of feline immunodeficiency virus (FIV) and fixed with paraformaldehyde were challenged with cell-free or cell-associated homologous virus obtained ex vivo. Complete protection was observed in animals challenged with cell-free virus 4 months after completion of vaccination (p.v.) or with cell-associated virus 12 months p.v. In contrast, no protection was observed in cats challenged with cell-free virus 12 or 28 months p.v. or with cell-associated virus 37.5 months p.v. Prior to the 28- and 37.5-month challenges, the animals had received a booster dose of vaccine that had elicited a robust anamnestic immune response. These results show that vaccine-induced protection against ex vivo FIV is achievable but is relatively short-lived and can be difficult to boost.

Citing Articles

Env-expressing autologous T lymphocytes induce neutralizing antibody and afford marked protection against feline immunodeficiency virus.

Pistello M, Bonci F, Zabogli E, Conti F, Freer G, Maggi F J Virol. 2010; 84(8):3845-56.

PMID: 20130057 PMC: 2849480. DOI: 10.1128/JVI.02638-09.

Evaluation of feline monocyte-derived dendritic cells loaded with internally inactivated virus as a vaccine against feline immunodeficiency virus.

Freer G, Matteucci D, Mazzetti P, Tarabella F, Catalucci V, Ricci E Clin Vaccine Immunol. 2008; 15(3):452-9.

PMID: 18216184 PMC: 2268258. DOI: 10.1128/CVI.00421-07.

Role of Env in resistance of feline immunodeficiency virus (FIV)-infected cats to superinfection by a second FIV strain as determined by using a chimeric virus.

Giannecchini S, Pistello M, Isola P, Matteucci D, Mazzetti P, Freer G J Virol. 2007; 81(19):10474-85.

PMID: 17634241 PMC: 2045460. DOI: 10.1128/JVI.01064-07.

AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: protection from an intraclade challenge administered systemically or mucosally by an attenuated vaccine.

Pistello M, Matteucci D, Bonci F, Isola P, Mazzetti P, Zaccaro L J Virol. 2003; 77(20):10740-50.

PMID: 14512524 PMC: 224962. DOI: 10.1128/jvi.77.20.10740-10750.2003.

FIV vaccine development and its importance to veterinary and human medicine: a review FIV vaccine 2002 update and review.

Uhl E, Heaton-Jones T, Pu R, Yamamoto J Vet Immunol Immunopathol. 2002; 90(3-4):113-32.

PMID: 12459160 PMC: 7119750. DOI: 10.1016/s0165-2427(02)00227-1.

References

Cammarota G, Matteucci D, Pistello M, Nicoletti E, Giannecchini S, Bendinelli M . Reduced sensitivity to strain-specific neutralization of laboratory-adapted feline immunodeficiency virus after one passage in vivo: association with amino acid substitutions in the V4 region of the surface glycoprotein. AIDS Res Hum Retroviruses. 1996; 12(2):173-175. DOI: 10.1089/aid.1996.12.173. View

Giannecchini S, Matteucci D, Mazzetti P, Bendinelli M . Incubation time for feline immunodeficiency virus cultures. J Clin Microbiol. 1996; 34(8):2036-8. PMC: 229181. DOI: 10.1128/jcm.34.8.2036-2038.1996. View

Hosie M, Flynn J . Feline immunodeficiency virus vaccination: characterization of the immune correlates of protection. J Virol. 1996; 70(11):7561-8. PMC: 190824. DOI: 10.1128/JVI.70.11.7561-7568.1996. View

Cammarota G, Da Prato L, Nicoletti E, Matteucci D, Bendinelli M, Pistello M . Quantitation of feline immunodeficiency proviruses in doubly infected cats using competitive PCR and a fluorescence-based RFLP. J Virol Methods. 1996; 62(1):21-31. DOI: 10.1016/0166-0934(96)02085-x. View

Rigby M, Mackay N, Reid G, Osborne R, Neil J, Jarrett O . Immunogenicity of a peptide from a major neutralising determinant of the feline immunodeficiency virus surface glycoprotein. Vaccine. 1996; 14(12):1095-102. DOI: 10.1016/0264-410x(96)00060-6. View

Poignard P, Klasse P, Sattentau Q . Antibody neutralization of HIV-1. Immunol Today. 1996; 17(5):239-46. DOI: 10.1016/0167-5699(96)10007-4. View

Bishop S, Stokes C, Gruffydd-Jones T, Whiting C, Humphries J, Osborne R . Vaccination with fixed feline immunodeficiency virus (FIV) infected cells: protection, breakthrough and specificity of response. Vaccine. 1996; 14(13):1243-50. DOI: 10.1016/s0264-410x(96)00023-0. View

Pistello M, Cammarota G, Nicoletti E, Matteucci D, Curcio M, Del Mauro D . Analysis of the genetic diversity and phylogenetic relationship of Italian isolates of feline immunodeficiency virus indicates a high prevalence and heterogeneity of subtype B. J Gen Virol. 1997; 78 ( Pt 9):2247-57. DOI: 10.1099/0022-1317-78-9-2247. View

Hirsch V, Fuerst T, Sutter G, Carroll M, Yang L, Goldstein S . Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J Virol. 1996; 70(6):3741-52. PMC: 190250. DOI: 10.1128/JVI.70.6.3741-3752.1996. View

10.

Stott E . Anti-cell antibody in macaques. Nature. 1991; 353(6343):393. DOI: 10.1038/353393a0. View

11.

Yamamoto J, Hansen H, Ho E, Morishita T, Okuda T, Sawa T . Epidemiologic and clinical aspects of feline immunodeficiency virus infection in cats from the continental United States and Canada and possible mode of transmission. J Am Vet Med Assoc. 1989; 194(2):213-20. View

12.

Stanley S, Ostrowski M, Justement J, Gantt K, Hedayati S, Mannix M . Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med. 1996; 334(19):1222-30. DOI: 10.1056/NEJM199605093341903. View

13.

Fultz P, Nara P, Barre-Sinoussi F, CHAPUT A, Greenberg M, Muchmore E . Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. Science. 1992; 256(5064):1687-90. DOI: 10.1126/science.256.5064.1687. View

14.

Sabin A . Improbability of effective vaccination against human immunodeficiency virus because of its intracellular transmission and rectal portal of entry. Proc Natl Acad Sci U S A. 1992; 89(18):8852-5. PMC: 50019. DOI: 10.1073/pnas.89.18.8852. View

15.

Yamamoto J, Hohdatsu T, Olmsted R, Pu R, Louie H, Zochlinski H . Experimental vaccine protection against homologous and heterologous strains of feline immunodeficiency virus. J Virol. 1993; 67(1):601-5. PMC: 237403. DOI: 10.1128/JVI.67.1.601-605.1993. View

16.

Tozzini F, Matteucci D, Bandecchi P, Baldinotti F, Siebelink K, Osterhaus A . Neutralizing antibodies in cats infected with feline immunodeficiency virus. J Clin Microbiol. 1993; 31(6):1626-9. PMC: 265592. DOI: 10.1128/jcm.31.6.1626-1629.1993. View

17.

Israel Z, Edmonson P, Maul D, ONeil S, Mossman S, Thiriart C . Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccines. J Virol. 1994; 68(3):1843-53. PMC: 236647. DOI: 10.1128/JVI.68.3.1843-1853.1994. View

18.

Ahmad S, Lohman B, Marthas M, Giavedoni L, Haigwood N, Scandella C . Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus. AIDS Res Hum Retroviruses. 1994; 10(2):195-204. DOI: 10.1089/aid.1994.10.195. View

19.

Baldinotti F, Matteucci D, Mazzetti P, Giannelli C, Bandecchi P, Tozzini F . Serum neutralization of feline immunodeficiency virus is markedly dependent on passage history of the virus and host system. J Virol. 1994; 68(7):4572-9. PMC: 236384. DOI: 10.1128/JVI.68.7.4572-4579.1994. View

20.

Lombardi S, Garzelli C, Pistello M, Massi C, Matteucci D, Baldinotti F . A neutralizing antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity. J Virol. 1994; 68(12):8374-9. PMC: 237306. DOI: 10.1128/JVI.68.12.8374-8379.1994. View